IDH1 and central nervous system cancer: Such different results may be due to the heterogeneity of methods used for the identification of T lymphocytes and/or for the measurement of their density and their markers of function and may certainly be explained by the inclusion in the analyses of different subgroups of gliomas, differing in grading and molecular characteristics (for example, the inclusion of lower-grade gliomas that are IDH-mutated) [87].